Business Details
Your Trusted Partner for Pharmaceutical Innovation
Astra Zeneca is a global, science-led, patient-focused pharmaceutical company dedicated to accelerating the delivery of life-changing medicines. With a purpose-driven approach, we create enduring value for patients, society, the planet, and shareholders. Our values guide our decision-making, emphasizing scientific rigor, patient-centricity, ethical conduct, and innovation. We focus on strategic areas including oncology, bioPharmaceuticals, and rare diseases, supported by a robust pipeline of 198 projects. Our sustainability strategy integrates climate action, health equity, and resilient healthcare systems, reflecting our commitment to interconnected health. With over 94,000 employees worldwide, we foster an inclusive culture where diverse perspectives drive breakthroughs.Our global R&D centers in Cambridge, Gaithersburg, Boston, Gothenburg, Shanghai, and Beijing serve as hubs for innovation, enabling us to push scientific boundaries. We collaborate with academia, governments, and industry partners to accelerate medical advancements. Our financial strength, evidenced by $54.1 billion in total revenue and $13.6 billion invested in science, positions us to achieve our 2030 ambition of launching 20 new medicines and reaching $80 billion in revenue. Through transparency, ethical governance, and a focus on employee well-being, we maintain trust and authority in the pharmaceutical industry.
Services
Oncology Research
Rare Disease Therapies
Clinical Trials
Precision Medicine
Vaccine Development
Immune Therapies
Sustainability Initiatives
Research Collaborations
Drug Discovery
Global Health Programs
Highlights and features
- We invest $13.6 billion annually in scientific research and development.
- Our global R&D network spans five strategic centers across four continents.
- We prioritize patient-centric solutions through precision medicine and AI-driven drug discovery.
- Our sustainability strategy addresses climate action and health equity globally.
- We maintain a 77.5% reduction in greenhouse gas emissions since 2015.
What people say
Life-changing medicines
Strong R&D pipeline
Global impact
Sustainability leadership
Scientific expertise
Services
Oncology Research
We lead a revolution in cancer care through innovative medicines and collaborations. Our focus on eliminating cancer as a cause of death involves targeted therapies, immunotherapies, and precision medicine. With a pipeline of novel oncology treatments, we aim to transform patient outcomes globally.
Rare Disease Therapies
Our rare disease division develops therapies for conditions with significant unmet needs. Using advanced modalities like gene therapy and RNA technologies, we address diseases affecting small patient populations. Our Alexion subsidiary expands access to life-changing treatments worldwide.
Clinical Trials
We conduct global clinical trials across all therapy areas, leveraging AI and real-world data to accelerate development. Our trials focus on patient diversity and biomarker-driven enrollment to improve treatment efficacy and regulatory approval success rates.
Precision Medicine
Our precision medicine approach identifies patient-specific biomarkers to guide treatment decisions. By integrating genomics and digital health technologies, we deliver personalized therapies that maximize efficacy while minimizing side effects across multiple disease areas.
Sustainability Initiatives
We implement climate action plans to achieve net-zero emissions by 2030. Our sustainability efforts include renewable energy adoption, water stewardship programs, and partnerships to improve global health equity and healthcare system resilience.
People
Pascal Soriot
Chief Executive Officer
With over 25 years in pharmaceutical leadership, Pascal drives Astra Zeneca's innovation strategy. He focuses on scientific excellence and sustainable growth, leveraging his experience from Roche and Genentech to shape global healthcare solutions.
Kim Blomley
Head of Global Media Relations
Kim leads global media strategy, ensuring accurate scientific communication. With expertise in corporate messaging, she bridges complex pharmaceutical research with public understanding, maintaining Astra Zeneca's transparent industry leadership.
Christian Petrovic
Senior Director, Global Media Relations
Christian manages corporate sustainability communications, emphasizing climate action and health equity. His 15-year pharmaceutical experience shapes narratives connecting scientific innovation with societal impact through strategic media engagement.
Andy Barnett
Head of Investor Relations
Andy oversees investor communications, translating R&D progress into financial value. With deep market knowledge, he maintains transparent dialogue with shareholders about pipeline advancements and long-term growth strategies in oncology and rare diseases.
Elizabeth Walton
Director of Investor Relations
Elizabeth specializes in respiratory and immunology portfolio communications. She provides detailed insights into clinical trial outcomes and market access strategies, ensuring investors understand the commercial potential of emerging therapies in chronic disease areas.
Questions
What therapeutic areas does AstraZeneca focus on?
We prioritize oncology, bioPharmaceuticals (including cardiovascular, renal, and metabolic diseases), and rare diseases through our Alexion division.
How does AstraZeneca approach drug discovery?
We combine AI-driven platforms, precision medicine, and global collaborations to accelerate development from target identification to clinical trials.
What sustainability initiatives do you have?
Our net-zero roadmap includes renewable energy adoption, 77.5% emissions reduction since 2015, and health equity programs improving access to care.
Where are your research centers located?
Our strategic R&D hubs operate in Cambridge (UK), Gaithersburg (US), Boston (US), Gothenburg (Sweden), Shanghai, and Beijing.
How do you ensure clinical trial diversity?
We implement global recruitment strategies and digital tools to enroll representative patient populations across all trial phases.
What partnerships does AstraZeneca pursue?
We collaborate with academia, biotechs, and governments to access cutting-edge technologies in gene therapy, AI, and diagnostic development.
Videos
